PharmiWeb Recruiter Blog

LEIDEN, the Netherlands, September 26, 2022 / B3C newswire / -- SeraNovo BV (Leiden, The Netherlands) is pleased to announce the closing of a multi compound deal with Ildong Pharmaceutical (Seoul, South Korea), a pharmaceutical company engaged in the research and development of small molecules in the field of neuroscience and oncology.

Novo Nordisk Foundation launches major investment to develop the first quantum computer dedicated to life sciences research and the green transition

New facility adds supply assurance and capacity to enable more life-saving vaccines and therapies

Significant investment will enable world-class discovery research, innovation in data science and digital health and collaborations in the Bay Area

–Gilead Foundation’s Creating Possible Fund™ Reflects Broad and Ongoing Commitment to Health Equity –

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, today announced its partnership with TMA Precision Health, a company on a mission to improve the lives of rare disease patients everywhere, offering clinical whole genome sequencing to rare disease patients as the first step in diagnosing and treating disease with more personalized medicine.

Bagsværd, Denmark and Redmond , W A , US , 12 September 2022 – Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities.

National effort builds on Foundation’s longstanding commitment to helping patients in underserved communities receive high-quality, equitable care

– New state-of-the art manufacturing facility is designed to enable the reliable production of Orca Bio's investigational cell therapies from late-stage clinical development through potential commercialization –

• State-of-the-Art Platform Comprised of Established and Emerging Technologies Across a Wide Spectrum of RNA Discovery, Development and Delivery, Excluding RNAi Therapeutics
• Strategic Partnership with Beam Therapeutics Provides Access to Beam’s RNA and Delivery Technologies for Multiple Therapeutics Applications
• Founding and Leadership Teams Comprised of Recognized Scientific Pioneers, Successful Drug Developers and Accomplished Biopharma Executives
•  Initial Funding Led by ARCH Venture Partners with Participation from a16z Bio + Health and Newpath Partners

CAMBRIDGE, Mass. – September 7, 2022 – Orbital Therapeutics launched today with a vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.